Clinical trial
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
NCT00059631 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00059631 |
|---|---|
| Title | Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone |
| Official title | Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone in Patients With Advanced Androgen-Independent Prostate Cancer (AI-PCa) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Mitoxantrone (Novantrone), Bortezomib (PS-341) |
| Enrollment | 42 |
| Start date | Mar 20, 2003 |
| Primary completion | Jun 17, 2015 |
| Completion | Jun 17, 2015 |
| First posted | Apr 30, 2003 |
| Last update posted | Nov 15, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: